Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States: Supplementary Data

Published: 08-04-2020| Version 2 | DOI: 10.17632/6gdm5j3fjb.2
Contributors:
Yasser Albogami,
Amir Sarayani,
Juan Hincapie-Castillo,
Almut Winterstein

Description

The data include tables and figures that may interest the readership of the following article: Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States

Files